Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, announces significant progress in its drug discovery collaboration with AstraZeneca.

22 Jan 2015

Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.

22 Jan 2015

ENIGMA scientists discover eight genetic mutations that may erode or boost brain tissue

In the largest collaborative study of the brain to date, researchers from the Keck School of Medicine of the University of Southern California led a global consortium of 190 institutions to identify eight common genetic mutations that appear to age the brain an average of three years. The discovery could lead to targeted therapies and interventions for Alzheimer's disease, autism and other neurological conditions.

22 Jan 2015

Microscopic spheres of calcium phosphate linked to AMD development

Microscopic spheres of calcium phosphate have been linked to the development of age-related macular degeneration (AMD), a major cause of blindness, by UCL-led research.

21 Jan 2015

Alzheimer's drug Aricept (donepezil) linked to serious side effects

New warnings have been added to the prescribing information for the Alzheimer's drug Aricept (donepezil) advising of the risk of two rare but potentially serious conditions: muscle breakdown (rhabdomyolysis) and a neurological disorder called neuroleptic malignant syndrome (NMS).

21 Jan 2015

Walnuts may improve cognitive function

Eating walnuts may improve performance on cognitive function tests, including those for memory, concentration and information processing speed according to new research from the David Geffen School of Medicine at The University of California, Los Angeles, led by Dr. Lenore Arab. Cognitive function was consistently greater in adult participants that consumed walnuts, regardless of age, gender or ethnicity.

21 Jan 2015

Abnormal attachment of sugar to BACE1 enzyme leads to formation of Aβ plaques in the brain

Researchers at the RIKEN-Max Planck Joint Research Center in Japan have demonstrated that hallmark symptoms of Alzheimer's disease can be reduced when sugars are prevented from binding to one of the key enzymes implicated in the disease. The new findings, reported in EMBO Molecular Medicine, show that abnormal attachment of a particular sugar to the enzyme BACE1 is a critical factor leading to the formation of Aβ plaques in the brain, and that plaques were reduced and cognitive performance improved when this action was prevented in mice through loss of the enzyme GnT-III.

17 Jan 2015

MRIGlobal awarded $54 million NIH contract to provide support for drug development

MRIGlobal today announced that it has been awarded a $54 million, 10-year program from the National Institute of Neurological Disorders and Stroke to provide support for the development and manufacturing of drug candidates for ultimate use in human clinical trials.

15 Jan 2015

Better Eyes for Longer Life without Alzheimer's research project opens to everyone

The Alzheimer's Association puts a fine point on the truism that the risk of developing Alzheimer's disease or some other form of cognitive impairment increases with age: (They expect that) 7 million of those who reach 85 by 2050 will have Alzheimer's disease (AD).

15 Jan 2015

Vascular and Alzheimer's-related brain abnormalities cause dementia in older people

A growing body of research suggests that the most common cause of dementia in older people is a mix of vascular and Alzheimer's-related brain abnormalities, and that approximately half of people who die with Alzheimer's also have evidence of strokes in their brains. Furthermore, when strokes and hallmark Alzheimer's plaques and tangles are combined, it increases a person's likelihood of experiencing dementia.

15 Jan 2015

Venom of cone snails provides leads for possible treatment of cancer, addiction

While considered a delicacy in some parts of the world, snails have found a more intriguing use to scientists and the medical profession offering a plethora of research possibilities. Cone snails are marine mollusks, just as conch, octopi and squid, but they capture their prey using venom.

15 Jan 2015

Study: Depression, behavioral changes may occur in Alzheimer's disease before memory declines

Depression and behavioral changes may occur before memory declines in people who will go on to develop Alzheimer's disease, according to new research at Washington University School of Medicine in St. Louis.

14 Jan 2015

Man-made insulin nasal spray may improve memory in adults with Alzheimer's-related dementia

A man-made form of insulin delivered by nasal spray may improve working memory and other mental capabilities in adults with mild cognitive impairment and Alzheimer's disease dementia, according to a pilot study led by researchers at Wake Forest Baptist Medical Center.

9 Jan 2015

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Migraine affects 36 million Americans, can have a major impact on patients' quality of life, and even on their relationships. The World Health Organization estimates that migraine is the third most prevalent medical disorder in the world, the 4th most disabling among women and the 7th most disabling overall.

8 Jan 2015

Research findings could lead to new drug design for neurological diseases

A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.

8 Jan 2015

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Jan 2015

New study finds that exercise may improve lives of Parkinson's disease patients

Exercise may help people with Parkinson's disease improve their balance, ability to move around and quality of life, even if it does not reduce their risk of falling, according to a new study published in the December 31, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Jan 2015

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

First successful vaccination of deer against chronic wasting disease

Researchers at NYU Langone Medical Center and elsewhere say that a vaccination they have developed to fight a brain-based, wasting syndrome among deer and other animals may hold promise on two additional fronts: Protecting U.S. livestock from contracting the disease, and preventing similar brain infections in humans.

23 Dec 2014

Alzheimer's Disease News and Research

Further Reading

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

ENIGMA scientists discover eight genetic mutations that may erode or boost brain tissue

Microscopic spheres of calcium phosphate linked to AMD development

Alzheimer's drug Aricept (donepezil) linked to serious side effects

Walnuts may improve cognitive function

Abnormal attachment of sugar to BACE1 enzyme leads to formation of Aβ plaques in the brain

MRIGlobal awarded $54 million NIH contract to provide support for drug development

Better Eyes for Longer Life without Alzheimer's research project opens to everyone

Vascular and Alzheimer's-related brain abnormalities cause dementia in older people

Venom of cone snails provides leads for possible treatment of cancer, addiction

Study: Depression, behavioral changes may occur in Alzheimer's disease before memory declines

Man-made insulin nasal spray may improve memory in adults with Alzheimer's-related dementia

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Research findings could lead to new drug design for neurological diseases

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

New study finds that exercise may improve lives of Parkinson's disease patients

Newron, Zambon announce re-submission of safinamide NDA to FDA

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

First successful vaccination of deer against chronic wasting disease

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News